Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) physicians have helped create the first set of clinical guidelines for treating patients with pulmonary hypertension in sickle cell disease. Elizabeth ...
Mar 18, 2014
0
0
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.
Mar 15, 2014
0
0
The development of new, more effective vasodilators to treat pulmonary arterial hypertension (PAH) has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking ...
Jan 7, 2014
0
0
(Medical Xpress)—The world's leading voices in the fight against pulmonary hypertension have compiled a special publication detailing the breakthrough research into the causes of this debilitating vascular disease.
Jan 6, 2014
0
0
(HealthDay)—Patients with systemic sclerosis have elevated levels of CXCL4, which predicts disease risk and progression, according to a study published online Dec. 18 in the New England Journal of Medicine.
Dec 19, 2013
0
0
Multiple types of cells are needed for patients to recover from surgery or to restore life to tissues that have lost circulation. University of Georgia researchers have identified how the cells involved in the final stage ...
Dec 6, 2013
0
1
A team of UW-Madison researchers has discovered important biomechanical changes in human arteries that could increase understanding of how pulmonary hypertension leads to heart failure.
Nov 11, 2013
0
0
(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.
Oct 23, 2013
0
0
(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.
Oct 9, 2013
0
0
Researchers at Saint Louis University School of Medicine have discovered a novel interaction between prostacyclin (PGI2) analogs and phosphodiesterase 5 (PDE5) inhibitors, two groups of drugs used in the treatment of pulmonary ...
Sep 20, 2013
0
0
